Free tool
FAERS Monitor: Navitrux
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 220436 or its brand name (Navitrux, Fosaprepitant Dimeglumine). Reports on generic versions are filed under their own applications.
Reports
1,762
Serious
1,552
88% of reports
Hospitalization
916
Death reported
394
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea329
- infusion related reaction291
- alopecia256
- fatigue248
- hypersensitivity241
- pyrexia231
- arthralgia229
- confusional state223
- glossodynia220
- helicobacter infection219
- duodenal ulcer perforation217
- discomfort214
- gastrointestinal disorder214
- pruritus214
- abdominal discomfort213
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 4 |
| 2012 | 5 |
| 2013 | 29 |
| 2014 | 53 |
| 2015 | 48 |
| 2016 | 58 |
| 2017 | 63 |
| 2018 | 97 |
| 2019 | 92 |
| 2020 | 118 |
| 2021 | 140 |
| 2022 | 200 |
| 2023 | 166 |
| 2024 | 215 |
| 2025 | 282 |
| 2026 | 186 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,397 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| duodenal ulcer perforationSignal | 217 | 358.8 | 316.1 | 74,839 |
| helicobacter infectionSignal | 219 | 259.8 | 229.2 | 55,035 |
| glossodyniaSignal | 220 | 118.5 | 104.6 | 25,284 |
| infusion related reactionSignal | 291 | 52.6 | 47.4 | 14,669 |
| discomfortSignal | 214 | 42.0 | 37.0 | 8,521 |
| gastrointestinal disorderSignal | 214 | 28.6 | 25.2 | 5,679 |
| confusional stateSignal | 223 | 16.5 | 14.6 | 3,251 |
| alopeciaSignal | 256 | 15.6 | 13.9 | 3,506 |
| hypersensitivitySignal | 241 | 15.5 | 13.8 | 3,283 |
| abdominal discomfortSignal | 213 | 15.2 | 13.4 | 2,825 |
| pyrexiaSignal | 231 | 8.0 | 7.1 | 1,424 |
| dyspnoeaSignal | 329 | 6.9 | 6.3 | 1,712 |
| pruritusSignal | 214 | 6.7 | 5.9 | 1,040 |
| arthralgiaSignal | 229 | 6.6 | 5.8 | 1,099 |
| fatigueSignal | 248 | 3.8 | 3.4 | 529 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.